We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Rectangle Image
News

Axol Appoints Paul Andrews to Scientific Advisory Board

Rectangle Image
News

Axol Appoints Paul Andrews to Scientific Advisory Board

Read time:
 

Axol Bioscience has announced that Paul Andrews will join as their Scientific Advisory Board Member. Dr Andrews is an expert in the industrial application of stem cells in phenotypic screening, having previously used this platform to identify agents that steer cell fate. He will aid Axol in ensuring its commercially available human primary and induced pluripotent stem cell (iPSC)-derived cells continue to enable the development of pathophysiologically-relevant systems for industrial and academic research.

Paul Andrews, BSc PhD FRSB is Director of Operations at the National Phenotypic Screening Centre (NPSC), a new open collaborative venture based at the Universities of Dundee, Oxford and Edinburgh. Dr Andrews also sits on the editorial board for Current Research in Drug Discovery and is a Fellow of the Royal Society of Biology. He has been a Trustee of the British Society of Cell Biology, Advisory Board Member of the Scottish Stem Cell Network and was team leader in Cellartis/Cellectis Stem Cells. Prior to this he was team leader for the Stem Cell Technology Programme in the Drug Discovery Unit at The University of Dundee and has over 20 years of postdoctoral research experience in cell and molecular biology. 

Dr Paul Andrews, SAB Member, Axol Bioscience said, ‘The time is right to move away from the reductionist target-based approach for drug screening towards using an information-rich phenotypic platform. I’m certain this approach will have a major role to play in the future of drug discovery and development. Axol’s experience in providing a wide range of iPSC-derived cell types and genome editing services to industry offers researchers a reputable resource to tackle complex diseases.’ Dr Yichen Shi, CEO, Axol Bioscience commented, ‘We’re excited to have Dr Andrews on board. His interdisciplinary approach and experience using human iPSCs and embryonic stem cells (ESCs) for high throughput phenotypic drug screening will help ensure we continue to supply cells that drive the development of pathophysiologically-relevant assays to improve drug discovery efficiency.’

Advertisement